← Leaderboards
Joseph S Pagano
University Of North Carolina Chapel Hill
$26,597,625
Attributed
$26,597,625
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$26,597,625 · 10
By mechanism
T32$16,226,769 · 1
P01$5,495,623 · 3
R01$3,194,933 · 2
P30$946,568 · 2
R21$733,732 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Shannon Celeste Kenney$30,359,662
- Nancy Joan Raab-Traub$18,607,374
- Blossom A Damania$35,988,246
- Winston C Patterson$23,185,986
- Wagner R Duarte$364,500
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralGene ExpressionCellsGenesEpstein-Barr Virus LatencyViral CarcinogenesisTranscription FactorMalignant NeoplasmsB-LymphocytesAffectUbiquitinBaseHuman Herpesvirus 4ProteinsTumorigenesisChemical CarcinogenesisOncogenic VirusesIn VivoPathway InteractionsDeubiquitinationCell CycleLymphoid CellEpstein Barr VirusB-Cell Lymphomas
Grant awards (69)
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$287,947
P01 · FY2020 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$280,182
P01 · FY2019 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$9,134
P01 · FY2019 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$287,949
P01 · FY2018 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$9,134
P01 · FY2018 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$317,029
P01 · FY2017 · CA · contact PI
Integrated Training in Cancer Model Systems$24,651
T32 · FY2017 · CA · contact PI
Integrated Training in Cancer Model Systems$777,300
T32 · FY2016 · CA · contact PI
Project 2 - Membrane trafficking in EBV malignancies: Implication of deubiquitinase UCH-L1$308,775
P01 · FY2016 · CA · contact PI
Cellular and Viral Regulation of EBV Latency: Implication of Ubiquitin-Editing En$291,447
P01 · FY2015 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,272,857
T32 · FY2014 · CA · contact PI
Cellular and Viral Regulation of EBV Latency: Implication of Ubiquitin-Editing En$283,593
P01 · FY2014 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,174,051
T32 · FY2013 · CA · contact PI
Cellular and Viral Regulation of EBV Latency: Implication of Ubiquitin-Editing En$273,960
P01 · FY2013 · CA · contact PI
PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS$178,600
R21 · FY2013 · AI · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$57,445
T32 · FY2013 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$54,231
T32 · FY2013 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,272,412
T32 · FY2012 · CA · contact PI
Cellular and Viral Regulation of EBV Latency: Implication of Ubiquitin-Editing En$291,445
P01 · FY2012 · CA · contact PI
PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS$228,000
R21 · FY2012 · AI · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$54,231
T32 · FY2012 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$51,963
T32 · FY2012 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,010,602
T32 · FY2011 · CA · contact PI
Cellular and Viral Regulation of EBV Latency: Implication of Ubiquitin-Editing En$291,444
P01 · FY2011 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,107,477
T32 · FY2010 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,105,050
T32 · FY2009 · CA · contact PI
New EBV Therapies for treating malignancies$346,086
R01 · FY2009 · HL · contact PI
CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY$345,354
P01 · FY2009 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$49,915
T32 · FY2009 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,078,399
T32 · FY2008 · CA · contact PI
New EBV Therapies for treating malignancies$346,086
R01 · FY2008 · HL · contact PI
CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY$337,644
P01 · FY2008 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,004,882
T32 · FY2007 · CA · contact PI
New EBV Therapies for treating malignancies$346,086
R01 · FY2007 · HL · contact PI
CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY$336,699
P01 · FY2007 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,031,377
T32 · FY2006 · CA · contact PI
New EBV Therapies for treating malignancies$356,423
R01 · FY2006 · HL · contact PI
CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY$225,812
P01 · FY2006 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$47,385
T32 · FY2006 · CA · contact PI
Basic Mechanisms of Viral and Chemical Carcinogenesis$1,077,688
T32 · FY2005 · CA
New EBV Therapies for treating malignancies$355,800
R01 · FY2005 · HL
CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY$219,235
P01 · FY2005 · CA
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$1,007,304
T32 · FY2004 · CA
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$898,464
T32 · FY2003 · CA
Interferon Regulatory Factor 7 EBV Latency &Oncogenesis$327,132
R21 · FY2003 · AI
EBV VECTORS FOR TARGETED GENE THERAPY OF B-LYMPHOMAS$180,850
R01 · FY2003 · HL
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$784,466
T32 · FY2002 · CA
CELLULAR REGULATION OF TYPE III EBV LATENCY$434,203
P01 · FY2002 · CA
INTERFERON REGULATORY FACTORS CELL CYCLE AND EBV LATENCY$246,628
R01 · FY2002 · AI
EBV VECTORS FOR TARGETED GENE THERAPY OF B-LYMPHOMAS$180,850
R01 · FY2002 · HL
MAJOR PROGRAMS FOR CANCER CENTER SUPPORT$157,506
P30 · FY2002 · CA
CORE--DEVELOPMENTAL PROJECTS$157,506
P30 · FY2002 · CA
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$651,120
T32 · FY2001 · CA
CELLULAR REGULATION OF TYPE III EBV LATENCY$434,203
P01 · FY2001 · CA
INTERFERON REGULATORY FACTORS CELL CYCLE AND EBV LATENCY$240,977
R01 · FY2001 · AI
EBV VECTORS FOR TARGETED GENE THERAPY OF B-LYMPHOMAS$180,850
R01 · FY2001 · HL
MAJOR PROGRAMS FOR CANCER CENTER SUPPORT$158,272
P30 · FY2001 · CA
CORE--DEVELOPMENTAL PROJECTS$158,272
P30 · FY2001 · CA
MAJOR PROGRAMS FOR CANCER CENTER SUPPORT$157,506
P30 · FY2001 · CA
CORE--DEVELOPMENTAL PROJECTS$157,506
P30 · FY2001 · CA
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$601,946
T32 · FY2000 · CA
INTERFERON REGULATORY FACTORS CELL CYCLE AND EBV LATENCY$233,959
R01 · FY2000 · AI
CELLULAR REGULATION OF TYPE III EBV LATENCY$230,434
P01 · FY2000 · CA
EBV VECTORS FOR TARGETED GENE THERAPY OF B-LYMPHOMAS$180,338
R01 · FY2000 · HL
BASIC MECHANISMS OF VIRAL AND CHEMICAL CARCINOGENESIS$31,553
T32 · FY2000 · CA
CORE--DEVELOPMENTAL PROJECTS$0
P30 · FY2000 · CA
CORE--DEVELOPMENTAL PROJECTS$0
P30 · FY2000 · CA
MAJOR PROGRAMS FOR CANCER CENTER SUPPORT$0
P30 · FY2000 · CA
MAJOR PROGRAMS FOR CANCER CENTER SUPPORT$0
P30 · FY2000 · CA